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ABSTRACT Coagulation factor V (FV) is a large plasma glycoprotein with functions in both the pro- and anticoagulant
pathways. In carriers of the so-called R2-FV haplotype, the FV D2194G mutation, in the C2 membrane-binding domain, is
associated with low expression levels, suggesting a potential folding/stability problem. To analyze the molecular mechanisms
potentially responsible for this in vitro phenotype, we used molecular dynamics (MD) and continuum electrostatic calculations.
Implicit solvent simulations were performed on the x-ray structure of the wild-type C2 domain and on a model of the D2194G
mutant. Because D2194 is located next to a disulﬁde bond (S-S bond), MD calculations were also performed on S-S bond
depleted structures. D2194 is part of a salt-bridge network and investigations of the stabilizing/destabilizing role of these ionic
interactions were carried out. Five mutant FV molecules were created and the expression levels measured with the aim of
assessing the tolerance to amino acid changes in this region of molecule. Analysis of the MD trajectories indicated increased
ﬂexibility in some areas and energetic comparisons suggested overall destabilization of the structure due to the D2194G
mutation. This substitution causes electrostatic destabilization of the domain by ;3 kcal/mol. Together these effects likely
explain the lowered expression levels in R2-FV carriers.
INTRODUCTION
Coagulation factor V (FV) is the precursor of an essential
procoagulant cofactor that accelerates FXa-catalyzed pro-
thrombin activation. It is a large glycoprotein that is
structurally and functionally homologous to factor VIII
(FVIII), the two proteins sharing the domain organization
A1-A2-B-A3-C1-C2. Activation of FV involves proteolytic
removal of the large B domain, converting the procofactor
into the fully active cofactor FVa (Nicolaes and Dahlback,
2002; Mann and Kalafatis, 2003). Interestingly, FV also has
a reported anticoagulant function in the APC-mediated
inactivation of FVIIIa (reviewed by Nicolaes and Dahlback,
2002). FV and FVIII interact with many proteins and bind to
cell surfaces, essentially via the C2 domain. The three-
dimensional (3D) structure of the C2 domains of FV/FVIII
was initially predicted using a combination of threading and
comparative modeling based on the structure of galactose
oxidase (Villoutreix et al., 1998; Pellequer et al., 1998;
Baumgartner et al., 1998). Despite very low sequence
identity (;10%) between the C domains of FV/FVIII and
galactose oxidase, the overall 3D fold of the predicted
structures was correct as seen from comparison with recently
reported x-ray structures of the isolated C2 domains of FV
and FVIII (Macedo-Ribeiro et al., 1999; Pratt et al., 1999).
These C domains (also called discoidin domains) exhibit
a distorted jelly-roll b-barrel motif, consisting of eight major
antiparallel strands arranged in two b-sheets. The amino- and
carboxy-terminal segments are clamped together by the only
disulﬁde bond (S-S bond) present in this module (C2038-
C2193). The modeled and experimental structures of the C2
domain of FV allowed for proposal of key regions involved
in membrane binding (Nicolaes et al., 2000; Kim et al.,
2000). This FV membrane-binding motif consists of several
exposed hydrophobic side chains located essentially on loop
structures (e.g., the 2060-loop), surrounded by a ring of basic
residues. In human plasma, FV circulates as a mixture of two
isoforms, FV1 (glycosylated) and FV2 (not glycosylated)
that have slightly different molecular weights because of
partial N-linked glycosylation at N2181. This leads to
differences in membrane-binding behavior between FV1 and
FV2 (Rosing et al., 1993; Hoekema et al., 1997, Nicolaes
et al., 1999). Also, glycosylation at N2181 has been
proposed to modulate the FV expression levels (Nicolaes
et al., 1999).
The FV R2 haplotype, ﬁrst described in a cohort of
thromboembolic patients, encompasses several genetically
linked polymorphisms, that encode amino acid substitutions
(of which M385T, H1299R, M1736V, and D2194G are most
likely linked to the haplotype) in different domains of the
molecule (Lunghi et al., 1996; Bernardi et al., 1997; Castoldi
et al., 2000). There is no consensus from epidemiogical
studies if these polymorphisms are associated with venous or
arterial thrombosis. Yet, in vitro studies have demonstrated
that at least, the D2194G substitution in the FV C2 domain
induces a substantially impaired expression due to retention
of the mutant protein in the endoplasmic reticulum (ER),
a place where misfolded protein tends to be trapped and
degraded (Yamazaki et al., 2002). Thus the D2194G
substitution appears to affect the folding/structure/stability
of the C2 domains (Yamazaki et al., 2002; Van Der Neut
Kolfschoten et al., 2003) via mechanisms that are not fully
understood.
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It is a major challenge to establish the links between point
mutations, 3D structures, and disease states (Villoutreix,
2002; Bross et al., 1999; Wickner et al., 1999; Sinha and
Nussinov, 2001, Hilser et al., 1998; Taverna and Goldstein,
2002). Potential impacts of mutations on protein stability,
folding, and function can be investigated theoretically using
a single 3D conformation of the folded native protein as
a starting point (Wang and Moult, 2001) or via (short/long)
molecular dynamics (MD) simulations (Cregut and Serrano,
1999; Schiffer and van Gunsteren, 1996; Kazmirski et al.,
1995; Rizzuti et al., 2001). When a mutation involves
a charged residue that has ionic interactions with surround-
ing groups, some speciﬁc electrostatic computations can also
be performed to investigate the stabilizing or destabilizing
roles of salt bridges on the protein stability (Kumar and
Nussinov, 1999; Hendsch and Tidor, 1994; Lounnas and
Wade 1997; Barril et al., 1998; Dong and Zhou, 2002).
To study the potential impacts of the D2194G mutation on
the C2 domain of human FV, we used MD, electrostatic
computations and site-directed mutagenesis. In the native 3D
structure of the C2 domain, residue D2194 is partially
solvent exposed, fully conserved in the FV species and
located next to the C2038-C2193 disulﬁde bond. It is
involved in electrostatic interactions with the side chains of
K2101 and K2103. We hypothesized that the D2194G
substitution could affect the stability of the molecule due to
electrostatic destabilization and/or induce conformational/
ﬂexibility changes. Due to its position, directly juxtaposed to
the disulﬁde bridge in the C2 domain, the D2194G mutation
could also inﬂuence disulﬁde bond formation. We decided to
run MD simulations with an implicit solvent model on the
C2 domain of wild-type FV (WT-FV) and on the D2194G
mutant, in the presence or the absence of the C2038-C2193
bond. Simulations without the S-S bond were carried out to
examine some of the effects of this bond on the 3D structure
of the domain. Electrostatic computations were also run on
different C2 structures to further investigate the role of ionic
interactions in the 2194 area. Several mutant proteins
(D2194K, K2101E/K2103E, K2101E/K2103E/D2194K,
and C2038A/C2193A) were produced and the ﬁnal expres-
sion levels characterized to assess the overall sensitivity of
this region to amino acid changes. Taken together, our data
indicate that aspartate at position 2194 is important for the
stability of the domain and that the above amino acid
substitutions affect the stability and/or the conformation of
the domain.
COMPUTATIONAL METHODS
Molecular dynamics
Molecular dynamics simulations were carried out on the high resolution
x-ray structure (Macedo-Ribeiro et al., 1999) of domain C2 of WT-FV and
on a model of the D2194Gmutant. The x-ray structure of the humanWT-FV
C2 domain (Macedo-Ribeiro et al., 1999) was taken from the Protein Data
Bank (Berman et al., 2000) (entry 1czt; 1.8 A˚ resolution). There is no
experimental structure for the D2194G mutant and we have built an initial
3D model for this domain on the basis of the WT structure by simply
removing the D2194 side chain. The N-terminal group was acetylated in all
initial structures to account for the fact that this residue is linked to the C1
domain. MD simulations were performed: for the WT-C2 domain and the
mutant D2194G, with or without the disulﬁde bond C2038-C2193. The
same protocol for energy minimization and molecular dynamics was used
for all the relevant simulations. Calculations were performed using the
program CHARMm (Brooks et al., 1983) using CHARMm 22 parameters
on two Silicon Graphics (IRIX 6.5) Fuel V12 single 600-MHz processor
workstations (Mountain View, CA). Interactive analysis of the results was
performed in InsightII (running on SGI workstations) or with ICM (Molsoft,
La Jolla, CA) running on two Precision 530 Dell PC dual-2.4-GHz
processors driven by Red Hat Linux 7.3.
The importance of correct accounting for solvation effects during MD
simulations has been widely discussed. Because explicit treatment of solvent
is very time consuming and eventually not needed, several implicit methods
have been proposed for calculation of solvation effects in proteins (Bashford
andCase, 2000, Feig andBrooks, 2002).Wehave used in ourMDsimulations
the Generalized Born (GB) method as implemented by Dominy and Brooks
(1999) into the program CHARMm to account for the electrostatic
contribution to the solvation energy (Brooks et al., 1983) (version 27.b1 or
28.b1, Accelrys, San Diego, CA). The GB approximation is based on a two-
dielectric model and its mathematical form, for a molecule with arbitrary
shape, has been extensively parameterized (Dominy and Brooks, 1999).
The empirical Atomic Solvation Parameter (ASP) approach as proposed
by Wesson and Eisenberg (1992) with parameterization by Sharp et al.
(1991) was also applied to account for the nonpolar solvation energy. This
method assumes that the nonpolar (considered in the present article to be
the solvent-solvent cavity and solute-solvent van der Waals terms) solva-
tion free energy of the solute can be decomposed into a sum of atomic free
energy components that are proportional to the solvent accessible surface
(SAS) of atoms of type k: Ghydrophobic ¼ +sk SASk. Here we used sk ¼
12.3 cal/mol/A˚2 for the hydrophobic carbon atoms and sk ¼ 0.0 cal/mol/A˚2
for the other atoms as suggested by several research groups (Qiu et al.
1997; Morozov et al. 2003).
The charge-charge interactions were treated using Coulomb law with
a dielectric constant e ¼ 1 to be consistent with the GB parameterization.
The GB parameters proposed in Dominy and Brooks (1999) were used and
a dielectric constant of 80 was applied to represent the highly polarizable
solvent medium. For all nonbonded interactions we used a cutoff of 15 A˚
and a switch function.
Initial hydrogen positions were calculated using the HBUILD utility of
CHARMm. Deﬁnition of the charged state for the titratable groups in the
x-ray structure of WT-FV and the mutant D2194G before the MD
simulations was decided after electrostatic computations of the mean proton
occupancy (see below for computational details). The results indicated that
all Lys, Arg, Glu, Asp, and the C-terminal group are charged whereas the
remaining residues including His residues were found to be neutral. Only
K2148 was found not to be completely charged (calculated mean proton
occupancy q ¼ 0.4) at pH ¼ 7.
The initial 3D structures were energy minimized (1500 steps steepest
descent method or a tolerance of energy gradient of 0.15 kcal/mol/A˚) and
MD simulations were then performed on the minimized structures. The
temperature of the system was raised gradually from 240 to 300 K in 20 ps
followed by equilibration at 300 K for 50 ps. This was further continued by
a 900-ps production run of NVT-MD at 300 K with the Berendsen algorithm
(Berendsen et al. 1984) and the protein conformations were recorded every
1 ps. The time step was 1 fs and the SHAKE algorithm was used to elimi-
nate the high frequency hydrogen/heavy atom bond vibrations.
Electrostatic calculations
All electrostatic calculations (pKa, electrostatic free energies of stabiliza-
tion) were performed for the WT and mutants but only on the structures
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possessing the S-S bond. Thus, the x-ray structure of the WT, the structures
with the D2194G, D2194K, K2101E/K2103E, K2101E/K2103E/D2194K
substitutions (without simulations) were selected for computations. The
same calculations were also carried out on the last conformations of the MD
simulations for the WT and the D2194G mutant, as well as on 30 structures
sampled from the MD trajectories from 670 to 970 ps of the production run
(one structure selected every 10 ps).
Finite difference Poisson-Boltzmann energy calculations
For computation of electrostatic energies used in protonation states and
electrostatic stabilization calculations, we used the program UHBD (Davis
et al., 1991) that solves the Poisson-Boltzmann equation numerically on
a grid by the ﬁnite difference method (Warwicker and Watson, 1982; Sharp
and Honig, 1990; Yang et al., 1993). It has been previously proposed
(Antosiewicz et al., 1994) that a better agreement between calculated and
experimental pKa values of titratable groups can be obtained using a higher
protein dielectric constant (e.g., ein ¼ 20). However, in this work we use
ein ¼ 4, because accurate results for evaluation of salt-bridge energetic were
obtained earlier with this value (Hendsch & Tidor, 1994; Lounnas and
Wade, 1997; Barril et al., 1998). The protein atomic radii and charges were
based on the CHARMm 22 parameter set. The dielectric boundary between
the protein and solvent was deﬁned using the solvent accessibility surface
with probe sphere of radius 1.4 A˚ and 500 dots per atom for generation of the
surface. Initial boundary conditions were determined by calculating the
potential at each boundary point using the Debye-Huckel approximation. A
salt concentration of 0.15 M and salt exclusion radius of 2.0 A˚ were used in
the ﬁnite difference Poisson-Boltzmann (FDPB) calculations.
In the calculation of protonation states, ﬁrst the protein structures were
included into a grid of 45 3 45 3 45 points with a resolution of 2.5 A˚. A
focusing scheme proposed previously (Yang et al., 1993; Antosiewicz et al.,
1994) using four successive lattices with increasing grid resolution was
applied for calculation of electrostatic potentials created by every ionized
group. The last focusing run was done in a 3D grid of dimension of 20 nodes
and a resolution of 0.25 A˚ centered at the titration site. A procedure with two
focusing runs in boxes of dimension of 65 with resolution of 1.5 A˚, followed
by a box of dimension of 70 with a 0.3-A˚ resolution, was applied to calculate
the electrostatic energies involved in the calculation of electrostatic
stabilization of the charged triads (see below).
Protonation states
The FDPB method has been widely used for calculation of protein
protonation states (Bashford and Karplus, 1990; Yang et al., 1993;
Antosiewicz et al., 1994). To calculate intrinsic pKa value (pKint) of a given
titratable group (Tanford and Kirkwood, 1957), (the pKint is deﬁned as the
pKa that the group would have if all other titratable groups were neutral) one
unit charge at the protonation site of this group and all permanent partial
charges of the protein were taken into account.
The protonation state n of a protein with N titratable residues is
characterized by the protonation state vector dn(i), i¼ 1 toN, where dn(i)¼ 1
when the ith group is charged and 0 when it is neutral. The free energy of the
nth protonation state DGn is given by:
DG
n ¼ +
N
i¼1
dnðiÞ3 gðiÞ3 ð2:3RTðpH pKinti ÞÞ
1
1
2
+
N
i¼1
i6¼j
dnðiÞ3 dnðjÞ3DGij; (1)
where g(i) ¼ 1 or 1 for an acidic or basic group i, respectively, pKinti is the
intrinsic pKa value of the group i, and DG
ij is the electrostatic interaction
energy between groups i and j in their charged states deﬁned by d(i) and d(j).
In this work the protonation states of all studied structures were obtained at
pH 7.0 (Antosiewicz et al., 1994).
In the computation of electrostatic potentials fij due to the charge j at the
location of the charged site i, involved in pairwise interactions calculation
(DGij ¼ gifij), only a unit charge at the protonation site was included. The
protonation sites were set to the atoms: Cg of Asp, Cd of Glu, Cz of Arg, Nz
of Lys, Ne2 of His, OH of Tyr, C atom of main-chain C-terminus. The mean
proton occupancies q of titratable groups at pH 7 are computed by averaging
over the protonation states sampled by the Monte Carlo method based on the
DGn calculations (Antosiewicz and Porschke, 1989).
Electrostatic free-energy contributions to the protein
stability for salt-link triads
The electrostatic free energy, DDGtot, contributing to protein stability due to
a triad of charged amino acid residues in a protein (WT or mutants) was
calculated relative to a reference protein hydrophobic isosteres (an isostere is
deﬁned as a residue with the same conformation and position in the protein
as the original residue but neutral). The term DDGtot was calculated
following the procedure proposed by Hendsch and Tidor (1994):
DDG
tot ¼ DDGsol1DDGtriad1DDGpr: (2)
The three terms DDGsol, DDGtriad, DDGpr were computed as differences
between the energies of the protein and the protein with appropriate amino
acids involved into the ionic triad replaced to their respective hydrophobic
isosteres.
The desolvation electrostatic energy DGsol of the triad in a protein was
calculated as:
DG
sol ¼ DGsolA 1DGsolB 1DGsolC ; (3)
and DGsolA , DG
sol
B , and DG
sol
C are the electrostatic desolvation free energies of
each residue of the triad A, B, C, respectively. The electrostatic desolvation
energy DGsolv for taking a residue from solvent to protein environment is
given following Gilson and Honig (1988).
The electrostatic energy of internal interactions in the triad DGtriad was
presented as:
DG
triad ¼ DGABC  DGA  DGB  DGC; (4)
where DGABC is the electrostatic free energy of the protein involving only
the charges of the triad; DGA, DGB, DGC are the electrostatic free energies of
the protein involving the charges of only one of the triad residues A, B, or C,
respectively.
The electrostatic free energy of interactions between the triad and the rest
of the protein DGpr is calculated by:
DG
pr ¼ DGprot;triad  DGABC  DGprot: (5)
The three terms in Eq. 5 correspond to electrostatic free energy of the
protein when all protein charges are present (DGprot,triad); all charges are
present excluding the charges of the triad (DGprot), and only the charges of
the triad are present (DGABC).
These calculations were performed for investigation of the WT triad
(D2194, K2101, K2103 versus the mutant G2194, K2101, K2103). In the
calculation of these electrostatic energies of stabilization, the atomic partial
charges corresponding to CHARMm22 parameters were used (such charged
state of the groups is in agreement with our calculated mean proton
occupancies q at pH 7 for the WT and D2194G mutant). In the modeled MD
structures of WT and mutant D2194G all Lys, Arg, Glu, Asp, and C-term
residues were calculated to be charged and the other groups, including the
His residues were computed to be neutral.
For other C2 mutant structures (D2194K, K2101E/K2103E, K2101E/
K2103E/D2194K), residue E2103 in mutants K2101E/K2103E and
K2101E/K2103E/D2194K, as well as residue K2101 in mutant D2194K
were taken noncharged in the calculation of triad electrostatic stabilization,
as computed from the mean proton occupancies.
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EXPERIMENTAL PROCEDURES
Site-directed mutagenesis
Site-directed mutagenesis was performed using the Quick
Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) according to the manufacturer’s instructions to generate
new variant FV recombinant molecules: D2194K, K2101E/
K2103E, C2038A/C2193A. As a template we used the full-
length cDNA of human FV, coding for the FV2 isoform
(WT-N2181Q) described previously (Nicolaes et al., 1999).
A fourth mutant was constructed by mutagenesis of D2194
into K, using the K2101E/K2103E plasmid as a template.
The construction of an expression vector for recombinant FV
containing the R2-associated D2194G mutation has pre-
viously been described (Yamazaki et al., 2002). Two com-
plementary oligonucleotides (DNA Technology, Aarhus C,
Denmark) were used as mutagenic primers for each con-
struct, the sense oligo being:
59-GAACTCTTTGGCTGTAAGATTTACTAGAATTG-
39 (D2194K),
59-TTGATCTACTCGAGATCGAGAAGATAACGGC-
39 (K2101E/K2103E),
59-TGAGGTAAATGGAGCTTCCACACCCCTG-39
(C2038A), and
59-CTGGAACTCTTTGGCGCTGATATTTACTAG-39
(C2193A).
To ensure that during the mutagenesis no additional
mutations were introduced, a small polymerase chain re-
action (PCR) fragment containing the desired mutation(s)
was cut out of the PCR product by restriction endonucleases
and ligated into a new template that had been cleaved by the
same restriction enzymes. The presence of only the desired
mutations in each of the plasmids was checked by DNA
sequencing.
Transient expression of factor V
Recombinant Factor V plasmids were transiently coex-
pressed with a Green Fluorescent Protein-lamin construct
(GFP-lamin) in COS-1 cells using Fugene 6 Transfection
Reagent (Roche Molecular Biochemicals, Indianapolis, IN).
A transfection mixture was made by mixing 100 ml of
Optimem serum-free medium (Optimem with Glutamax I;
Gibco, Life Technologies, Gaithersburg, MD) with 7.5 ml
Fugene 6 Transfection Reagent, 2 mg of mutated pMT2-FV
and 0.5 mg pEGFP-lamin plasmid. This mixture was
incubated at room temperature for 20 min, before adding it
to ;80% conﬂuent monolayer of COS1 cells in 2 ml
Dulbecco modiﬁed Eagle medium (DMEM), supplemented
with L-glutamine. Transfection was allowed to proceed for
16 hr before replacing the transfection medium with fresh
DMEM, supplemented with L-glutamine, 10% fetal calf
serum, 100 IU/ml penicillin and 100 mg/ml streptomycin.
After 48 h posttransfection, cells were washed with phos-
phate-buffered saline and after trypsinisation, 25% of the
cells were harvested to quantitate the transfection efﬁciency
by ﬂow cytometry. The remainder of the cells was cultured
for an additional 28 h in 3 ml serum-free medium
supplemented with 0.1 mg/ml Albumax I (Gibco BRL; Life
Technologies) and 2.5 mM CaCl2.
FV antigen measurements in media
Conditioned media were collected in prechilled tubes and
centrifuged for 10 min at 200g to remove cells and cell
debris. The supernatant was aliquoted and stored at 808C.
The Factor V antigen levels in the media were determined by
a FV ELISA kit (Kordia, Leiden, The Netherlands). ELISA
standard curves were constructed with normal pooled plasma
from 81 healthy individuals.
RESULTS
Overall characteristics of the MD simulations
MD simulations were performed on the C2 domain of the
WT and of the D2194G mutant with or without the C2038-
C2193 S-S bond. The minimization procedure that was
applied to relax the structures yielded conformations with
root-mean-square deviations (RMSD) for heavy atoms
between the initial WT x-ray structure and the minimized
structure of 0.2 A˚. With regard to MD, for all studied
structures, the potential energy decreased during the ﬁrst 150
ps of the simulation and then stabilized. Therefore, the entire
production time interval (900 ps) was considered for the MD
analysis. For the wild type, the average RMS deviations for
the Ca atoms relative to the x-ray structure over the last 900
ps are 1.67 A˚ and 1.75 A˚, in the presence or absence of the
S-S bridge, respectively. For the mutant D2194G with or
without the disulﬁde bond, RMSD were 1.86 A˚ and 1.76 A˚,
respectively. Similar RMSD for the simulated structures
indicate that the mutation D2194G and the removal of the
disulﬁde bridge do not result in large structural rearrange-
ments (see below).
Fig. 1 A shows plots of the potential energy calculated
over the trajectories. The higher potential energy observed
for both mutant forms (irrespective of the presence of the S-S
bond) suggests that the D2194G mutation has destabilizing
effects (see below). Fig.1, B and C, show the Coulombic and
GB solvation energies of both WT forms (WT with or
without S-S bond) calculated during the MD trajectories. It
was previously proposed by Spassov et al. (1994) that
proteins containing no disulﬁde bonds are optimized electro-
statically as compared to molecules possessing disulﬁde
bridges. It is interesting to note that breaking the S-S bond in
the FV C2 domain leads to lower Coulombic energies during
the MD indicating optimization of electrostatic interactions.
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The lack of S-S bond apparently facilitates reorientation of
charged residues and formation of stronger favorable charge-
charge interactions. In contrast, more favorable Coulombic
interactions lead to less-favorable solvation energies. This
can be seen from the GB energies, which are higher for the
WT when the structure does not have the S-S bond. The van
der Waals interactions (not shown) were similar for all
trajectories and remained stable during the MD simulations.
Structural and ﬂexibility differences between
x-ray and simulated WT
The root mean square ﬂuctuations (RMSF) for the Ca atoms
of the C2 domain per residue (sampled over 900 structures)
were calculated. In Fig. 2 A the ﬂuctuations of the simulation
WT structures with and without S-S bond and the B factors
(Ca atoms) of the C2 x-ray structure are presented.
The calculated ﬂuctuations of simulated WT (with S-S
bond) are in good agreement with the B-factors. The zones of
greatest ﬂexibility in the simulated and crystal structures tend
to be similar but some differences are also noted. The loop
2140-2150 is very ﬂexible in the WT-simulated and crystal
structures. The membrane-binding loop (residues 2060-2067
including two key Trp residues 2063 and 2064) and residues
2130-2139 appear to be more ﬂexible in the crystal than in
the WT-simulated structure. Some differences between the
FIGURE 1 Energetic values obtained during the MD trajectories. (A)
Potential energy versus the time. The WT C2 domain is shown in black; WT
without S-S bond, blue; D2194 mutant, red; and D2194G mutant without
S-S bond, magenta. (B) Coulombic energy versus the time. The WT C2
domain is shown in black; WT without S-S bond, blue. (C) GB solvation
energy versus the time. The WT C2 domain is shown in black; WT without
S-S bond, blue.
FIGURE 2 Root mean square ﬂuctuations computed over the last 900 ps
of the MD simulations. (A) RMSF of the simulated WT structures with
(black) and without (blue) S-S bond and the B-factors (Ca atoms) of the C2
x-ray structure (red). (B) RMSF of the simulated mutant D2194G structures
with (black) and without (blue) S-S bond, (C) Ribbon diagram for the
averaged modeled structure of the D2194Gmutant over the last 900 ps of the
MD simulations color coded according to the calculated RMSF.
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B-factors of the crystal and calculated RMSF for the WT-
simulated structures are also seen for the region 2152-2162
that is found to be more rigid in the x-ray structure.
No signiﬁcant structural differences are present between
the x-ray and averaged simulation structure of the WT C2
domain (not shown). Important changes occur only for the
loop 2060-2067 involved in membrane binding, which
appears to be ﬂexible (i.e., it adopts two different con-
formations in the crystal structures) (Macedo-Ribeiro et al.,
1999). Some conformational changes also take place at the
level of the 2074-2080 loop, which is very ﬂexible in both
the x-ray and simulated WT structures.
Structural and ﬂexibility differences between
WT and mutant D2194 with S-S bond
Fig. 2 B shows the ﬂuctuations of modeled mutant D2194G
with or without the disulﬁde bridge. In Fig. 2 C the averaged
modeled structure for the D2194G mutant over the last 900
ps of the MD simulations is given color coded according to
the calculated RMSF. Comparisons of the ﬂexibilities in the
modeled WT and the mutant indicate that the regions 2075-
2085 and 2140-2150 are ﬂexible in both WT and D2194G
mutant (Fig. 2). The loop 2042-2053, situated nearby the
mutated residue, is more ﬂexible in the mutant structure. The
2060-2067 loop also becomes more ﬂexible in the D2194G
mutant. This is possibly caused by the increased mobility of
the loop 2042-2053.
Fig. 3 shows the last structure obtained from the
simulation for the WT protein domain and the D2194G
mutant (S-S bond present). These structures can be con-
sidered as representative of the MD simulations in the area of
residue 2194 because the calculated electrostatic stabili-
zation energies of a set of sampled MD conformations (see
below) are similar to those calculated for the last MD
structure. The regions showing structural changes upon the
D2194G substitution (in the presence of S-S bond) involve
the loop 2130-2139 and the C-terminal residues (the N-term
residues remain essentially unchanged). The D2194G mu-
tation does not affect the dynamical properties of these two
regions, which do not appear ﬂexible in the simulated WT
and D2194G mutant structures (Fig. 2), but the mutation
rather causes conformational changes. In the last simulation
structures (with S-S bond; Fig. 3), the loop 2130-2139 is
opened in the mutant as compared to the WT, the Ca of
N2132 shifts by ;3 A˚.
We also noted that upon mutation of D2194, the
nonﬂexible C-terminus (Tyr-2196) inserts into the structure
of the domain, attempting to ﬁll the hole created by the
D2194 to G substitution, probably also trying to compensate
for the missing negative charge of this mutant. These events
could lead to enhanced ﬂexibility of the loop 2042-2053 and
to conformational changes of the 2130-2139 region.
Structural and ﬂexibility differences between
structures with or without disulﬁde bond
It is evident from Fig. 2, A and B that the N-terminal (not
charged in the simulation because it is in vivo connected to
the C1 domain) and C-terminal regions of the WT and
mutant D2194G modeled structures become extremely
mobile in the absence of the disulﬁde bond. As a result,
important conformational changes occur at both termini.
Also, the ﬂexibility of the 2087-2093 and 2113-2121 loops
in the WT is enhanced upon removal of the S-S bridge. Loss
of the S-S bond also results in a decreased mobility and in
structural changes of the region 2152-2162 in both the
simulatedWT and D2194Gmutant. The observed changes in
the dynamical properties of C2 domain occurring upon S-S
bond disruption could inﬂuence the folding process.
Electrostatic contribution to the stability of the
triad K2101-K2103-D2194/K2101-K2103-G2194
The electrostatic free energies DDGtot of the triads K2101,
K2103, D2194 in the WT and K2101, K2103, G2194 in the
mutant, relative to their corresponding hydrophobic isoesters
were computed only for the structures possessing the S-S
bond. The electrostatic stabilization of the triad, taking into
account the mean proton occupancies at pH 7, calculated ﬁrst
on the x-ray structure and on the x-ray structure with simple
D2194G substitution without simulations are given in Table
1. The same calculations were also carried out on the last
conformations of the MD simulations for the WT and the
D2194G mutant, as well as on 30 structures sampled from
the MD trajectories from 670 to 970 ps of the production run
(one structure selected every 10 ps). The averaged energies
for the 30 MD conformations and the term contributing to
DDGtot with standard deviations are reported in Table 1.
Additional computations of the electrostatic stabilization
of the triad 2101, 2103, 2194 and the pKa values of titratable
groups were carried out for the mutants D2194K, K2101E/
K2103E, and K2101E/K2103E/D2194K. The stabilization
contributions and mean charges at pH 7 of the triad residues
are given in Table 2.
FIGURE 3 Ribbon diagram of the WT and D2194G C2 domain. The last
structures obtained in the simulations (with S-S bond) are shown and some
key residues are labeled (see text).
Analysis of the D2194G Mutation in Factor V 493
Biophysical Journal 86(1) 488–498
The DDG energies are well optimized for the structures
sampled from the MD simulations, relative to the x-ray
structure. The electrostatic energies obtained from averaging
over 30 conformations were similar to those for the ﬁnal
simulation structures of the WT and the mutant and the
relatively small standard deviations conﬁrm that the struc-
tures in the region of the mutation are very similar in the last
300 ps of the simulations.
In the simulated structures (30 conformations) strong
favorable charge-charge interactions for the triad (DDGtriad)
were obtained for the WT (11.46 kcal/mol), whereas in the
mutant no signiﬁcant electrostatic interactions were calcu-
lated. In all structures no large differences between the
simulated WT and the mutant were found for electrostatic
interactions of the triad with the rest of the protein DDGpr.
The averaged electrostatic stabilization due to the inter-
actions between the triad and the protein varies between
5.17 and 8.52 kcal/mol in the WT and mutant, res-
pectively. As can be expected, the presence of three partially
buried ionized amino acid residues causes larger unfavorable
desolvation energy DDGsol in the WT (19.83 kcal/mol)
compared to the mutant (14.56 kcal/mol).
The electrostatic stabilization values calculated for the
triad 2101, 2103, 2194 in the mutants D2194K, K2101E/
K2103E, K2101E/K2103E/D2194K demonstrate the desta-
bilizing effect of these mutations in comparison to elec-
trostatic stabilization energy of the triad in WT computed on
the x-ray structure.
Mutagenesis
To investigate the importance of the charged triad K2101,
K2103, and D2194 and of the S-S bond, several mutant FV
molecules were created. These mutagenesis experiments
were also performed to probe the tolerance of this region of
FV to amino acid substitution. To ensure that any effects
observed on expression levels of the recombinant proteins
were not due to altered glycosylation of the C2 domain,
which per se is a modulator of FV expression levels
(Nicolaes et al., 1999), all triad mutations were constructed
using a template that resulted in the production of only the
FV2 isoform (lacking a glycan structure at position N2181).
This construct will subsequently be called WT*. The effect
of the presently studied FV mutations on the ﬁnal levels of
FV expression in COS-1 cells, which do not express
endogenous FV, were quantitated by FV-ELISA. Results
were corrected for variations in transfection efﬁciency by
cotransfecting the pMT2-FV with a pEGFP-C1-lamin vector
as described in the Materials and Methods section.
FV antigen level in serum-free media, conditioned for 28 h
in cells expressing the WT FV-plasmid, ranged from 17.6 ng
to 26.9 ng/35 mm well (n¼ 6). In conditioned media of cells
transfected with the pMT2/FV-D2194G plasmid, the FV
antigen level was 53% as compared to WT (Fig. 4). This is in
line with previous observations by Yamazaki et al. (2002),
who found that the D2194G mutation is the major
determinant of low expression levels within the R2-poly-
morphism (Yamazaki et al., 2002). Compared to WT,
a seven- to eightfold reduction in FV expression levels was
observed for the mutants D2194K, K2101E/K2103E,
K2101E/K2103E/D2194K, and C2038A/C2193A (Fig. 4).
Together these data indicate that mutations in the C2-domain
of FV that interfere with the charged triad D2194, K2101,
and K2103 lower the amount of FV secreted by the cells.
Mutation of the S-S bridge results in decreased ﬁnal FV
expression. However, expression of the mutants studied was
not completely inhibited by these mutations as expression
levels[13% were achieved for all constructs.
DISCUSSION
Recently, it has been proposed that ;80% of missense
mutations associated with disease states are amino acid
substitutions that affect the stability of proteins by ;1–3
kcal/mol (Wang and Moult, 2001). Stability problems can be
due to loss of hydrogen bonds, of S-S bonds, overpacking,
backbone strain, and/or burial of charged residues. In silico
strategies can be used to investigate the potential roles of
a mutation on, for instance, protein stability.
TABLE 1 Electrostatic free-energy contributions of the triad to the protein stability (kcal/mol)K2101/K2103/D2194 versus
K2101/K2103/G2194
DDGtot DDGsol DDGtriad DDGpr
wt mut wt mut wt mut wt mut
X-ray 2.13 10.93 11.85 10.72 3.38 11.23 0.60 1.02
MD: last conformation 6.34 4.46 19.41 15.48 10.62 0.91 5.13 9.03
MD: 30 conformations 6.81 6 0.7* 4.6461.0 19.8361.1 14.5660.4 11.4661.2 0.6860.5 5.1760.95 8.5260.9
*Standard deviations
TABLE 2 Mutants D2194K, K2101E/K2103E/D2194K, and
K2101E/K2103E
Mean charges at pH 7 of the triad:
Mutants 2101 2103 2194 DDGtot
D2194K 0.00 0.98 1.00 13.46
K2101E/K2103E/
D2194K
0.99 0.00 1.00 0.31
K2101E/K2103E 0.68 0.00 0.86 11.97
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In the present study, MD simulations (970 ps) were
executed on the C2 domain of WT FV and the D2194G
mutant that is present in carriers of the FV-R2 gene. Because
this mutation could potentially act on the formation of the
nearby C2038-C2193 S-S bond and/or the conformation of
the N-term/C-term residues, simulations of the WT and
D2194G S-S bondless structures were compared. Electro-
static computations were performed to investigate the
energetics of the WT K2101-K2103-D2194 triad and of
several mutants. Mutagenesis experiments and secretion
levels were also used to probe further the 2194 region of the
FV C2 domain (mutants were: D2194G, D2194K, K2101E/
K2103E, K2101E/K2103E/D2194K, C2038A/C2193A) be-
cause observed secretion efﬁciencies often relate to mutant
stability in vitro. These experimental data were correlated
with theoretical work while trying to include in our reasoning
the fact that protein-engineering methods usually probe
several physical contributions at the same time (e.g., electro-
static, steric, and entropic) (Lounnas and Wade, 1997)
whereas theoretical investigations may not.
A key step after MD computations is to evaluate the
accuracy of the calculations, through for instance evaluation
of RMSD, potential energy versus time and others (Figs. 1
and 2). Yet, although MD simulations with implicit solva-
tion models have been found of reasonable accuracy, some
authors suggest that despite low RMSD between the
simulated structures and the starting x-ray model, the
conformations of the simulated molecules are of poor quality
(Simonson, 2001). We thus investigated several structures of
the simulated WT with the energy strain utility included in
the ICM package (Molsoft) (Maiorov and Abagyan, 1998).
The simulated WT and mutant C2 domains had similar
structural features as the starting high-resolution x-ray
structure. Secondary structure contents in the starting x-ray
and simulated structures (WT or mutant) computed using the
method of Kabsch and Sander (1983) were similar.
Furthermore, the protein core of the WT or mutant C2
domain remained stable during the simulations performed on
structures in the absence of the S-S bond, despite increased
ﬂexibility/conformational changes in some regions of the
modeled structures (Figs. 2 and 3). These results as well as
the low RMSD calculated between the x-ray and modeled
structures together with the ICM evaluations conﬁrm that the
implicit solvation method and simulation protocol used here
are appropriate.
It has been shown that physical energy functions similar to
the one used in this study can identify native-like structure
from misfolded protein models and that low-quality 3D
structures tend to unfold during a simulation (Dominy and
Brooks, 2002; Feig and Brooks, 2002). Although we did not
observe unfolding of the D2194G mutant we noted that its
total potential energy (with or without S-S bond) is
signiﬁcantly higher than the one of the WT (Fig. 1). Thus,
in this speciﬁc case, investigation of the potential energy
suggests overall destabilization of the protein due to the
mutation.
We then analyzed trajectories obtained for the WT C2
structure (with or without S-S bond). It is known that
disulﬁde bonds in proteins can inﬂuence the stability as well
as the folding pathway and the efﬁciency of folding
(Kowalski et al., 1998; Omura et al., 1992; Parodi, 2000).
Generally, loss of a native disulﬁde bond reduces stability
and such mutant proteins may not be able to fold; secretion
can be impeded or delayed. Yet, in some situations, removal
of S-S bonds does not seem to affect the 3D structure of
a protein nor its function. In the simulation of the WT C2
domain with or without S-S bond, the protein core remained
stable. However, the increased mobility of the two termini, in
the absence of S-S bond could impair correct folding/
stability of the domain and damage interaction with the C1
domain. The WT protein without S-S bond does not express
well, suggesting folding/stability problems. Similar folding/
stability/expression problems were also noticed when re-
moving S-S bond(s) in retinoschisin, a discoidin-domain-
containing protein (Wu and Molday, 2003).
The potential energies of the WT C2 domain (with or
without S-S bond) are similar and one would not expect
folding/stability problems, but S-S bond depleted 3D
structures have to be analyzed with special care. It appears
that removing the disulﬁde bond in the FV C2 domain
FIGURE 4 Transient expression of FV proteins in
serum-free culture medium COS-1 cells were transiently
transfected to express WT-FV or the FV mutants. FV
antigen levels were measured in the culture media by
ELISA. Bars represent the means 6 standard deviations
(n ¼ 6). The mean value of WT-FV was 23.8 ng/35 mm
well and is assigned to be 100% in this ﬁgure. This WT-
FV construct was used as a template for the D/G mutation
and to construct the WT* plasmid (which only expresses
the FV2 isoform). There was no signiﬁcant difference
between the expression levels of the WT FV-plasmid and
the WT* plasmid, the WT* plasmid serving as a template
for the other FV mutants (nomenclature: D2194G (D/G),
D2194K (D/K), K2101E/K2103E (KK/EE), K2101E/
K2103E/D2194K (DKK/KEE), and C2038A/C2193A
(CC/AA)).
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facilitates optimization of some energy terms (thus lower
the total potential energy). This hypothesis is supported by
the observation that electrostatic interactions are optimized
in proteins that do not contain S-S bond as compared to
molecules containing S-S bonds (Spassov et al., 1994).
Thus, potential energies for the WT C2 domain with or
without S-S bond cannot be directly correlated with
expression levels. In addition, it can be noticed in the WT
and D2194G that the region 2152-2162 is less ﬂexible in
the structure without the S-S bond. This is consistent with
previous MD simulations showing that removal of S-S bond
can decrease the ﬂexibility of large portions of a protein
(Rizzuti et al., 2001).
The protein core of the D2194G mutant with or without
the S-S bond remained also stable during the simulation.
However, some regions become more rigid or more ﬂexible
due to the mutation (Fig. 2). For the mutant protein without
the S-S bond we observe signiﬁcantly higher ﬂexibilities
within the N-term residues as compared to the WT
(simulation without S-S bond). This suggests potential
folding/stability problems and/or damaged interaction with
the C1 domain. Also it is probable that the increased
ﬂexibility of the N-term residues due to the D2194G
mutation affects the formation of the nearby S-S bond. A
possible in vivo scenario could be that mutant molecules
(either D2194G or S-S bond free structure) could be
marginally stable and could equilibrate between the folded
state and an ensemble of unfolded conformations. This latter
population could then be recognized inside the ER and be
partially retained and degraded. This hypothesis would be in
fact in good agreement with the observed low expression
levels of these mutants.
FV C2 domain residue D2194 is involved in electrostatic
interactions with the side chains of K2101 and K2103.
Conservation (full or partial) of ionic interaction in this
region of FV or FVIII suggests that these salt bridges could
be important for the stability/structure of the C2 domain
(Table 3). It has been noted that conserved salt bridges
important for the stability of proteins are often buried
(Schueler and Margalit, 1995) whereas in the C2 domain, the
2101-2103-2194 triad is partially exposed. However, surface
salt bridges can also be important for protein stability (Strop
and Mayo, 2000; Dong and Zhou, 2002). In fact, salt bridges
can be stabilizing or destabilizing depending on their
environment (Kumar and Nussinov, 1999, 2001; Schutz
and Warshel, 2001). In the present study, we assumed that
the D2194G mutation could alter the stability of the FV C2
domain. Comparison of the electrostatic free energies
(DDGtot) of the 2101-2103-2194 triad between the WT FV
C2 domain and the D2194G mutant shows electrostatic
destabilization due to the mutation by ;3 kcal/mol. This
value is in the range of what has been observed by Wang and
Moult (2001). Therefore, we suggest that the D2194G
mutation destabilizes the domain and that this modiﬁed
structure could be detected by the proofreading apparatus
inside the cells.
To understand better the reactions taking place at the
level of residue 2194, other mutants were created in vitro
and in silico. Changing the distribution of charged groups in
the 2194 area could underline the importance of the salt-
bridge network and could provide information about
tolerance to amino acid substitutions. Computations of
electrostatic energies of the 2101-2103-2194 triad in the
mutants D2194K (D/K, thus three expected positive
charges), K2101E/K2103E (KK/EE, thus three expected
negative charges), K2101E/K2103E/D2194K (DKK/KEE,
modiﬁcation of the distribution of charges) calculated on
the rigid structures (see Table 2) also show destabilization
effects in comparison to the WT (x-ray structure). The
D2194K, K2101E/K2103E, K2101E/K2103E/D2194K mu-
tants show lower expression levels than the D2194G
mutant. These experimental data correlate well with the
calculated electrostatic destabilizations excluding the
K2101E/K2103E/D2194K (DKK/KEE) mutant. Generally,
it is expected that mutations leading to the positioning of
three negatively or positively charged groups close in space
will be destabilizing, as observed here in the case of the
D2194K (D/K) and K2101E/K2103E (KK/EE) substitu-
tions (Table 2). These mutants are thus predicted to be less
stable than the D2194G mutant and this correlates well with
the experimental expression levels. On the other hand, we
initially hypothesized that the mutant K2101E/K2103E/
D2194K (DKK/KEE) would form a stabilizing salt-bridge
triad that could mimic the WT protein. However, the
calculated proton occupancies at pH 7 show that 2103 is not
charged whereas in the WT the three triad residues are
ionized. This indicates that the distribution of charges in the
K2101E/K2103E/D2194K mutant is not favorable as
compared to the one of the WT. Although DDGtot suggests
that the mutated triad is slightly stabilizing, apparently, in
this case, additional structural features have to be integrated
in the analysis.
In summary, the D2194G substitution in the C2 domain
seems to electrostatically destabilize the structure, as shown
by computer calculations. Low expression levels were
observed for this mutant, suggesting also potential stability
and/or folding problems. Our experimental and MD/
electrostatic data shows that the right distribution of charges
in the 2194 region of the FV C2 domain is essential to the
TABLE 3 Multiple sequence alignment in the area of FV residue
2194 and surrounding area
2101 2103(buried) 2194
* * *
hFV_C2 : . . .ANNNKQWLEIDLLKIKKITAIIT. . .. . .. . ..LELFGCDIY
bFV_C2 : . . .ANNNNQWLQIDLLKIKKITAIVT. . .. . .. . ..LELFGCDMY
pigFV_C2 : . . .ANNNNQWLQIDLLKIKKITAITT. . .. . .. . ..LELFGCDIY
hFVIII_C2 : . . .VNNPKEWLQVDFQKTMKVTGVTT. . .. . .. . ..MEVLGCEAQ
mouseFVIII_C2 : . . .VNDPKQWLQVDLQKTMKVTGIIT. . .. . .. . ..LEILGCEAQ
pigFVIII_C2 : . . .VSSAEEWLQVDLQKTVKVTGITT. . .. . .. . ..LEVLGCEAQ
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stability and the presence of an S-S bond is required for the
stability/folding of this essential coagulation protein.
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